Skip to main content
Premium Trial:

Request an Annual Quote

Always Something to Worry About

Biotech CEOs are now more concerned about insurers than the Food and Drug Administration's regulatory process, reports Luke Zimmerman at Xconomy, drawing on a new survey put out by BayBio, the California Healthcare Institute, and PwC of 157 biotech CEOs in California.

"Getting FDA approval is now one step in the process," Gail Maderis, BayBio's CEO, tells him. "We're seeing a shift in concern from the FDA to insurance coverage. From a company's very early days, corporate partners and venture capitalists now want to know that if a product gets to the market, will it be reimbursed?"

Zimmerman notes that the shift comes at a time of high numbers of new product approvals by FDA, but also at a time of closer scrutiny of rising healthcare costs by insurers. Additionally, the upholding of the Patient Protection and Affordable Care Act of 2010 by the Supreme Court, and the subsequent re-election of President Barack Obama "dashed whatever hopes biotech executives may have had for a return to the days of virtually unlimited product pricing power," he adds.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.